Professor Sir Mene Pangalos wins Lifetime Achievement Award at the BIA’s Gala Dinner

Professor Sir Mene Pangalos, Executive Vice-President (retiring) of BioPharmaceuticals R&D at AstraZeneca, has received the prestigious BioIndustry Association (BIA) Lifetime Achievement Award at the organisation’s annual gala dinner. This award is based on nominations from the BIA Board and recognises Mene's transformative impact on AstraZeneca, the UK life sciences sector and people living with disease. Mene led AstraZeneca's pharmaceutical discovery and early development through a key period of growth and innovation and was a driving force for scientific excellence and collaboration. Joining the company in 2010, Mene transformed AstraZeneca’s approach to R&D, fostering deeper academic and industry partnerships, pioneering Open Innovation programmes, and building a culture that values truth-seeking in science. Mene's passion extends beyond his leadership role. He retains a keen interest in neuroscience, drug discovery, mentoring the next generation of scientists and sharing his expertise with over 150 peer-reviewed publications.

BIA Gala Key 008.jpg
© BIA
Professor Sir Mene Pangalos, Executive Vice-President (retiring) of BioPharmaceuticals R&D at AstraZeneca

His influence extends far beyond AstraZeneca. Mene is a leading figure in UK science, holding prestigious positions on boards such as The Francis Crick Institute, Cambridge University's Judge Business School, and Absci Corp. His dedication to fostering collaboration and innovation is evident from roles on the Medical Research Council, co-chairing the Life Sciences Council's Expert Group, and sitting on the UK Life Sciences Industrial Strategy Implementation Board.

Mene's contributions to medical science have been widely recognized. He is a Fellow of the Royal Society, the Academy of Medical Sciences, the Royal Society of Biology, and Clare Hall – University of Cambridge. In 2019, he was knighted by Her Majesty the Queen for his exceptional service to UK science and also received the 2019 Prix Galien Medal, Greece for his scientific research.

An important part of this legacy is AstraZeneca’s new R&D Discovery Centre (DISC) in Cambridge. This state-of-the-art facility, which is the largest research facility in the UK, was spearheaded by Mene and embodies his vision for collaborative scientific innovation – and is poised to play a crucial role in the future success of AstraZeneca and of the UK life science industry.

Steve Bates OBE, BIA’s CEO said: “Throughout his career Mene has championed a broad ecosystem approach to translating bioscience for patient benefit – from his time at university in London to the top of RD at a global biopharmaceutical company. He has formed key collaborations between academia and companies, large and small, in the UK and beyond, and his bold sector leadership was ably demonstrated during the pandemic.”

Professor Sir Mene Pangalos said: “I would like to express my immense gratitude for this great honour. This award really is a recognition of the contributions of all the people and teams I have worked with throughout my career. True innovation in medicine is only possible when we work together, towards a common goal: it's only thanks to the shared commitment of our scientists, our dedicated healthcare workers, and especially our patients and their families – that we can turn science into the life-changing new medicines for those who need them most.

BIA Gala Key 005.jpg
© BIA
Professor Sir Mene Pangalos being presented witha  Lifetime Achievement Award by BIA's Chair, Dan Mahony

The BIA gala delivered a night of celebration and collaboration, culminating in the launch of its Charity partnership with RNID with a fundraising and awareness activity for the 12 million people in the UK affected by deafness, hearing loss, or tinnitus. The coveted evening was attended by the brightest minds in UK biotech, the life science sector and business: industry leaders, member companies, and Andrew Griffith, Minister of State for Science, Innovation, and Technology.

Ends

Note to editors.

For more information, contact Alina O’Keeffe, Associate Director, Marketing and Communications, BIA on [email protected].

About the BioIndustry Association (BIA)

 

More news and updates 

Deep Biotech will deliver a more sustainable future, and BIA is its new voice

Deep Biotech encompasses innovative companies harnessing the power of engineering biology to tackle humanity's most pressing challenges, from environmental pollution to climate change. From cultivating meat without animals to crafting bio-based materials that replace harmful plastics, Deep Biotech offers a sustainable roadmap for a greener future. 

Professor Sir Mene Pangalos wins Lifetime Achievement Award at the BIA’s Gala Dinner

Mene led AstraZeneca's pharmaceutical discovery and early development through a key period of growth and innovation and was a driving force for scientific excellence and collaboration. Joining the company in 2010, Mene transformed AstraZeneca’s approach to R&D, fostering deeper academic and industry partnerships, pioneering Open Innovation programmes, and building a culture that values truth-seeking in science.

Resilient UK biotech sector lands £1.8 billion investment in 2023

New report highlights sector's strength, investor confidence and long-term returns. London-quoted biotechs also continue to outperform UK and US markets over the long term, having made substantial gains during the pandemic that have not been lost.   

BIA unveils new data: UK leads Europe in cell and gene therapy as sector makes significant strides  

The UK is cementing its position as a global leader in cell and gene therapy, according to a new report released today by the UK BioIndustry Association (BIA), in collaboration with Citeline.  

BIA reaches 600 member companies, announces new board and leadership restructure 

The UK’s innovative trade association for life science and biotech companies, BioIndustry Association (BIA), today announces that it has reached 600 companies in membership for the first time ever, alongside new Board and staff appointments for 2024.

BIA announces its Charity Partnership for 2024 with RNID

BIA is thrilled to announce its charity partnership of the year for 2024 with RNID, the national charity supporting the 12 million people in the UK who are deaf, have hearing loss or tinnitus. 

BIA responds to the Chancellor's Autumn Statement 2023

Life science spin-outs, start-ups and scale-ups are key drivers of the UK’s innovation-based economy and crucial for discovering and developing new medicines to save lives in the NHS. The UK is home to a third of life science startups founded in Europe since 2012 and companies like them are responsible for nearly two-thirds of medicines being developed globally.

bioProcessUK to celebrate biotech’s shining stars 

The BioIndustry Association (BIA) will honour two distinguished individuals for their exceptional contributions to the innovative life sciences and biotech sector.

UK biotech fundraising picks up with best quarterly total since 2021

The UK biotech sector secured a substantial total of £563 million in venture capital and public financing during the three months spanning June to August 2023, data published today by the UK BioIndustry Association (BIA) and Clarivate shows.

Rare disease companies call for UK leadership in supporting access to new treatments

A group of companies developing innovative new medicines for rare diseases, working together through their trade association, is calling for the UK to lead greater collaboration between stakeholders, and uptake of best practice both in the UK and internationally, to improve access to new treatments for patients.

 

More within